Home Compare GMAB.CO vs INCY
Stock Comparison · Industry comparison · Biotechnology

Genmab A/S vs Incyte: Which Stock Looks Stronger in 2026?

yte holds the cleaner structural position, with the lead spread across growth and profitability. Genmab A/S does not offset that deficit through any equally strong structural edge elsewhere. On the market side, yte is in better shape — its trend is intact while Genmab A/S's trend has broken down. That puts structure and market broadly in agreement — yte's lead looks more confirmed than conflicted.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

The lead is spread across growth and profitability, rather than sitting in one isolated gap. Incyte Corporation leads by 39 points on the overall comparison score.

INDUSTRY COMPARISON

Both operate in: Biotechnology

This comparison is based on industry proximity, not on functional trajectory similarity. GMAB.CO and INCY share the same industry classification.

For a similarity-based comparison, see how Genmab A/S and yte each position within their functional peer groups in AssetNext.

Peer-Relative Score
GMAB.CO
Genmab A/S
45
Peer-Score
Signal qualityHigh
vs
INCY
Incyte Corporation
84
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

Score differences across key dimensions.

Dimension spread: GMAB.CO vs INCY Profitability 46 91 Stability 40 73 Valuation 66 86 Growth 17 83 GMAB.CO INCY
Gap Ranking
#1 Growth +66
#2 Profitability +45
#3 Stability +33
#4 Valuation +20
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for GMAB.CO and INCY Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer GMAB.COINCY Relative valuation Structural strength

Incyte Corporation looks stronger both structurally and on relative valuation.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Growth
Incyte Corporation ranks near the top of the group on growth; Genmab A/S sits in the weaker half.
Profitability
On profitability, the same pattern holds: both are strong, but Incyte Corporation still leads clearly.
Growth — Dominant Gap
GMAB.CO
17
INCY
83
Gap+66in favour of INCY

Revenue growth reinforces the category-level growth lead.

What else supports the lead

Capital efficiency adds support, with a 75-point ROIC advantage.

What this means for the comparison

The lead is built on both growth and profitability, making it broader than a single-dimension result.

Explore full peer positioning in AssetNext

Break down the GMAB.CO vs INCY comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Similar growth-and-profitability comparisons

Explore how GMAB.CO and INCY each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.